Christine Desbiens
Chercheuse associée
Axe Oncologie
Publications
Voir tout-
article Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE, Olson JA, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the …
JAMA Oncol 6 (3), 2020.
-
article Mitera G, Earle C, Latosinsky S, Booth C, Bezjak A, Desbiens C, Delouya G, Laing K, Camuso N, Porter G
Choosing Wisely Canada cancer list: ten low-value or harmful practices that should be avoided in cancer care
J Oncol Pract 11 (3), 2015.
-
rapport Desbiens C, Hogue JC, Lévesque Y
Primary breast angiosarcoma: avoiding a common trap
, , p. 2011, ISBN: , .
Projets
- NSABP Breast Cancer Treatment Protocols, du 1997-02-01 au 2025-12-25
- Vers des trajectoires de soins en cancer du sein personnalisées en fonction du risque et des besoins des patientes: une étude de faisabilité et d'acceptabilité, du 2023-04-01 au 2026-07-31
- COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib , du 2024-03-12 au 2029-12-25
- Comparative effectiveness of opioid versus opioid-free post-discharge analgesia after outpatient breast surgery: A randomized controlled trial, du 2024-07-23 au 2029-12-25
- Exploring the impact for COVID-19 pandemic on women with breast cancer in Quebec, du 2021-12-01 au 2023-09-30
- OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy , du 2024-04-26 au 2025-02-28
- From survival to quality of life: developing and implementing priorities- and values-based personalized supportive and rehabilitation care pathways with and for people with advanced breast cancer, du 2024-07-15 au 2024-10-15